GlassScriptPhysician profile
Kristen B Osterrieder
NPI 1235460064
$9,455.84
in general payments reported to CMS, 2019-2025
34 companies · $949 in 2025
The $949 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,152 · 2022: $3,424 · 2023: $1,461 · 2024: $470 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,880.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,263.60 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Lilly USA, LLC | $1,131.34 | 2021-2025 | Mounjaro, Humulin, Jardiance |
| Novo Nordisk INC | $1,098.36 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $925.58 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $632.00 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $591.29 | 2021-2025 | Tepezza, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $357.35 | 2021-2023 | Farxiga |
| Amneal Pharmaceuticals LLC | $322.01 | 2021-2023 | Unithroid |
| Ibsa Pharma INC. | $319.21 | 2021-2023 | Tirosint, Licart |
| Corcept Therapeutics | $284.67 | 2021-2025 | Korlym |
| Mannkind Corporation | $247.68 | 2022-2023 | Afrezza |
| Amarin Pharma, INC. | $229.81 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $207.08 | 2021-2025 | |
| Clarus Therapeutics INC. | $104.13 | 2021 | |
| Bigfoot Biomedical INC | $79.96 | 2021-2023 | Unity Diabetes Management System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $64.16 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $64.02 | 2022-2025 | |
| Radius Health, INC. | $60.56 | 2021-2024 | Tymlos |
| Merck Sharp & Dohme LLC | $56.31 | 2021 | |
| Embecta Corp. | $46.26 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ultragenyx Pharmaceutical INC. | $44.43 | 2021-2022 | |
| Zealand Pharma US, INC. | $40.73 | 2021 | |
| Esperion Therapeutics, INC. | $35.36 | 2021 | |
| Sequel Med Tech, LLC | $30.21 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.99 | 2022 | |
| Hologic Sales and Service, LLC | $26.50 | 2025 | Novasure |
| Alexion Pharmaceuticals, INC. | $25.60 | 2023 | Strensiq |
| Antares Pharma, INC. | $24.51 | 2022 | |
| Abbvie INC. | $24.50 | 2021 | |
| Tandem Diabetes Care, INC. | $21.23 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $19.69 | 2022 | |
| Eusa Pharma (US) LLC | $19.69 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $16.38 | 2023 | Imcivree |
| Takeda Pharmaceuticals U.S.A., INC. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Osterrieder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.